These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36379208)

  • 21. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.
    Termini R; Žihala D; Terpos E; Perez-Montaña A; Jelínek T; Raab M; Weinhold N; Mai EK; Grab AL; Corre J; Vergez F; Sacco A; Chiarini M; Giustini V; Tucci A; Rodriguez S; Moreno C; Perez C; Maia C; Martín-Sánchez E; Guerrero C; Botta C; Garces JJ; Lopez A; Tamariz-Amador LE; Prosper F; Bargay J; Cabezudo ME; Ocio EM; Hájek R; Martinez-Lopez J; Solano F; Iglesias R; Paiva A; Geraldes C; Vitoria H; Gomez C; De Arriba F; Ludwig H; Garcia-Guiñon A; Casanova M; Alegre A; Cabañas V; Sirvent M; Oriol A; de la Rubia J; Hernández-Rivas JÁ; Palomera L; Sarasa M; Rios P; Puig N; Mateos MV; Flores-Montero J; Orfao A; Goldschmidt H; Avet-Loiseau H; Roccaro AM; San-Miguel JF; Paiva B;
    Clin Cancer Res; 2022 Nov; 28(21):4771-4781. PubMed ID: 36074126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.
    Zavidij O; Haradhvala NJ; Mouhieddine TH; Sklavenitis-Pistofidis R; Cai S; Reidy M; Rahmat M; Flaifel A; Ferland B; Su NK; Agius MP; Park J; Manier S; Bustoros M; Huynh D; Capelletti M; Berrios B; Liu CJ; He MX; Braggio E; Fonseca R; Maruvka YE; Guerriero JL; Goldman M; Van Allen EM; McCarroll SA; Azzi J; Getz G; Ghobrial IM
    Nat Cancer; 2020 May; 1(5):493-506. PubMed ID: 33409501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact.
    Kunacheewa C; Manasanch EE
    Expert Rev Hematol; 2021 Dec; 14(12):1059-1069. PubMed ID: 34550841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
    Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
    Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments.
    Fernandez N; Perumal D; Rahman A; Kim-Schulze S; Yesil J; Auclair D; Adams H; Parekh S; Gnjatic S; Cho HJ
    Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):853-862. PubMed ID: 35945129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance.
    Mateos MV; Martínez-López J; Rodriguez Otero P; González-Calle V; Gonzalez MS; Oriol A; Gutiérrez NC; Ríos-Tamayo R; Rosiñol L; Alvarez Rivas MA; Bargay J; Gonzalez-Rodriguez AP; Alegre A; Escalante F; Iñigo Rodríguez MB; De La Rubia J; Teruel AI; de Arriba F; Palomera L; Hernández MT; Lopez Jiménez J; Reinoso-Segura M; García Mateo A; Ocio EM; Paiva B; Puig N; Cedena MT; Bladé J; Lahuerta JJ; San-Miguel JF;
    J Clin Oncol; 2024 Sep; 42(27):3247-3256. PubMed ID: 39038268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Smoldering Multiple Myeloma: Emerging Concepts and Therapeutics.
    Sundararajan S; Kumar A; Korde N; Agarwal A
    Curr Hematol Malig Rep; 2016 Apr; 11(2):102-10. PubMed ID: 26894382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study.
    Mateos MV; Hernández MT; Salvador C; Rubia J; de Arriba F; López-Corral L; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Bladé J; Lahuerta JJ; San-Miguel J
    Eur J Cancer; 2022 Oct; 174():243-250. PubMed ID: 36067617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer.
    Muchtar E; Kumar SK; Magen H; Gertz MA
    Leuk Lymphoma; 2018 Feb; 59(2):288-299. PubMed ID: 28592156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
    Usmani SZ; Hoering A; Ailawadhi S; Sexton R; Lipe B; Hita SF; Valent J; Rosenzweig M; Zonder JA; Dhodapkar M; Callander N; Zimmerman T; Voorhees PM; Durie B; Rajkumar SV; Richardson PG; Orlowski RZ;
    Lancet Haematol; 2021 Jan; 8(1):e45-e54. PubMed ID: 33357482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Smoldering multiple myeloma: evolving diagnostic criteria and treatment strategies.
    Visram A; Cook J; Warsame R
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):673-681. PubMed ID: 34889380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing treatment for smoldering myeloma: is earlier better?
    Hernández JÁ; Martínez-López J; Lahuerta JJ
    Expert Rev Hematol; 2019 May; 12(5):345-354. PubMed ID: 30907176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
    Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legieć W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špička I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;
    Lancet Haematol; 2022 Jun; 9(6):e403-e414. PubMed ID: 35550060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?
    Matarraz S; Paiva B; Diez-Campelo M; López-Corral L; Pérez E; Mateos MV; Giraldo P; Hernández MT; San Miguel JF; Orfao A;
    Haematologica; 2012 Oct; 97(10):1608-11. PubMed ID: 22511492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. How I approach smoldering multiple myeloma.
    Vaxman I; Gertz MA
    Blood; 2022 Aug; 140(8):828-838. PubMed ID: 35576526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The consultant's guide to smoldering multiple myeloma.
    Thorsteinsdottir S; Kristinsson SY
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):551-559. PubMed ID: 36485144
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Smoldering multiple myeloma: biology, clinical manifestations and management.
    Nsiala L; Bobin A; Levy A; Gruchet C; Sabirou F; Gardeney H; Cailly L; Manier S; Moya N; Tomowiak C; Guidez S; Leleu X; Decaux O
    Leuk Lymphoma; 2022 Mar; 63(3):518-529. PubMed ID: 34672244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation between Morphological Typing and Monoclonality of Bone Marrow Plasma Cells and Its Diagnostic Value for High-Risk Smoldering Multiple Myeloma].
    Xiao HJ; Wang QJ; Wu S; Dai XB; Zhuang YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1146-1151. PubMed ID: 39192411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Smoldering Multiple Myeloma: Who and When to Treat.
    Mateos MV; González-Calle V
    Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):716-722. PubMed ID: 28709797
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
    Jagannath S; Laubach J; Wong E; Stockerl-Goldstein K; Rosenbaum C; Dhodapkar M; Jou YM; Lynch M; Robbins M; Shelat S; Anderson KC; Richardson PG
    Br J Haematol; 2018 Aug; 182(4):495-503. PubMed ID: 29808907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.